Orelabrutinib | 奥布替尼 | MedChemExpress (MCE)

Orelabrutinib 产品活性：Orelabrutinib (ICP-022) 是一种强效、口服活性、不可逆的 Bruton 酪氨酸激酶 (BTK) 抑制剂，具有潜在的抗肿瘤活性。Orelabrutinib 可阻止 B 细胞抗原受体 (BCR) 信号通路的激活和 BTK 介导的下游生存通路的激活，抑制过度表达 BTK 的恶性 B 细胞的生长。 产品来源： https://www.medchemexpress.cn/orelabrutinib.html 研究领域：Protein Tyrosine Kinase/RTK 作用靶点：Btk In Vitro: With a proprietary formulation, Orelabrutinib (ICP-022) achieves high bioavailability comparing to other BTK inhibitors. In Vivo: Upon administration, Orelabrutinib (ICP-022) binds to and inhibits the activity of BTK. This prevents both the activation of the B-cell antigen receptor (BCR) signaling pathway and BTK-mediated activation of downstream survival pathways, inhibiting the growth of malignant B-cells that overexpress BTK. 相关产品：Drug Repurposing Compound Library Plus | FDA-Approved Drug Library Plus | FDA-Approved Drug Library Mini | Bioactive Compound Library Plus | Kinase Inhibitor Library | Protein Tyrosine Kinase Compound Library | FDA-Approved Drug Library | Anti-Cancer Compound Library | Drug Repurposing Compound Library | NMPA-Approved Drug Library | Orally Active Compound Library | FDA Approved & Pharmacopeial Drug Library | Anti-Blood Cancer Compound Library | Rare Diseases Drug Library | FDA-Approved Anticancer Drug Library | Heterocyclic Compound Library | Membrane Protein-targeted Compound Library | Cysteine Targeted Covalent Library | Autoimmune Disease Compound Library | Anti-Hematopathy Compound Library | Bioactive Compound Library Max | Ibrutinib | Acalabrutinib | Pirtobrutinib | Zanubrutinib | Fenebrutinib | Remibrutinib | Tolebrutinib | Nemtabrutinib | Sunvozertinib | Tirabrutinib | NX-2127 | Rilzabrutinib | Spebrutinib | Ibrutinib-biotin | Branebrutinib | QL47 | BMX-IN-1 | MT-802 | Luxeptinib | NX-5948 | Vecabrutinib | (Z)-LFM-A13 | CGI-1746 | Avitinib maleate | SJF620 | Ibrutinib-MPEA | PCI-33380 | GDC-0834 品牌介绍: MCE (MedChemExpress) 拥有数百种全球独家化合物，我们致力于为全球科研客户提供最新最全的高品质小分子活性化合物；10,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领域；设有专业的实验中心和严格的质控、验证体系；提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告，确保产品的高纯度、高品质；产品的生物活性多经各国客户实验验证；Nature, Cell, Science 等多种顶级期刊及制药专利收录了MCE客户的科研成果；专业团队跟踪最新的制药及生命科学研究进展，为您提供全球最新的活性化合物；与世界各大制药公司及知名科研机构建立了长期的合作。

Orelabrutinib | 奥布替尼 | MedChemExpress (MCE)信息由MedChemExpress (MCE)为您提供，如您想了解更多关于Orelabrutinib | 奥布替尼 | MedChemExpress (MCE)报价、型号、参数等信息，欢迎来电或留言咨询。

注：该产品未在中华人民共和国食品药品监督管理部门申请医疗器械注册和备案，不可用于临床诊断或治疗等相关用途